Pulmonx faces a critical inflection point as revenue growth has decelerated into a 8.7% contraction in 2026Q1, signaling potential saturation or adoption headwinds for its Zephyr Valve system. Despite maintaining robust gross margins of 77.9%, the company's in...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | -$0.24+14.3% vs -$0.28 | $23M+1.6% vs $22M |
Q2 2026 Apr 29, 2026 | -$0.33+0.0% vs -$0.33 | $21M+0.8% vs $20M |
Q2 2026 Mar 4, 2026 | -$0.25+35.9% vs -$0.39 | $23M+4.0% vs $22M |
Q4 2025 Nov 12, 2025 | -$0.34+15.0% vs -$0.40 | $22M-1.0% vs $22M |
Deutsche Bank AG purchased a new stake in Pulmonx Corporation (NASDAQ: LUNG) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 402,316 shares of the company's stock, valued at approximately $523,000. Deutsche Bank AG owned approximately 0.94% of
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Benchmark LUNG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pulmonx Corporation (LUNG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.00 | $84.47M | -1.50 | 8.01% | -59.67% | -77.19% | — | |
| $69.06 | $1.99B | 14.12 | 13.6% | 15.03% | 17.62% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $18.09 | $1.03B | -10.52 | 37.22% | -32.54% | -30.62% | — | |
| $87.07 | $5.19B | 40.88 | 11.66% | 9.22% | 9.07% | — |
Pulmonx Corporation (LUNG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Pulmonx Corporation (LUNG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jun 4, 2026·SEC
Apr 29, 2026·SEC
Get notified when LUNG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pulmonx Corporation (LUNG) stock FAQ — growth, dividends, profitability & financials explained
Pulmonx Corporation (LUNG) reported $87.4M in revenue for fiscal year 2025. This represents a 337% increase from $20.0M in 2018.
Pulmonx Corporation (LUNG) grew revenue by 8.0% over the past year. This is steady growth.
Pulmonx Corporation (LUNG) reported a net loss of $48.1M for fiscal year 2025.
Pulmonx Corporation (LUNG) has a return on equity (ROE) of -77.2%. Negative ROE indicates the company is unprofitable.
Pulmonx Corporation (LUNG) had negative free cash flow of $30.7M in fiscal year 2025, likely due to heavy capital investments.
